Aclaris Therapeutics (ACRS) Fundamental Analysis: Revenue, Earnings & Valuation

7.06 / 10

Outperform

Fundamental evaluation scores 7.1/10 (Outperform). Strengths include a low cost‑of‑sales ratio (26.7%) and moderate current‑liabilities‑to‑total‑liabilities (49.9%). However, YoY revenue growth is sharply negative (‑58.2%), dragging the outlook despite overall solid financial health.

Analysis Checks(7/10)

Revenue-MV

Value-3.75

Score1/3

Weight14.75%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value-58.19

Score1/3

Weight-1.16%

1M Return-0.38%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.39%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value49.92

Score2/3

Weight1.15%

1M Return0.36%

PB-ROE

Value0.96

Score3/3

Weight37.41%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.42

Score3/3

Weight2.60%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.44%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-58.19

Score1/3

Weight-0.91%

1M Return-0.30%

Cost of sales ratio (%)

Value26.72

Score3/3

Weight0.86%

1M Return0.26%

Asset-MV

Value-0.55

Score3/3

Weight52.14%

1M Return11.61%

Is ACRS fundamentally strong?

ACRS scores 7.06/10 on fundamentals and holds a Discounted valuation at present. Backed by its -50.20% ROE, -829.58% net margin, -7.69 P/E ratio, 4.84 P/B ratio, and 69.01% earnings growth, these metrics solidify its Outperform investment rating.